Articles tagged with Neuroprotection
Researchers propose using low-dose lithium orotate to slow dementia progression in mild cognitive impairment, leveraging established neuroprotective mechanisms. The approach aims to mitigate kidney and thyroid risks associated with higher-dose formulations, offering a potentially accessible and inexpensive treatment option.
GLP-1 RAs improve mitochondrial function, reduce oxidative stress, enhance autophagy, and attenuate inflammaging. They affect all 12 hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, insulin resistance, and dysbiosis.
A new study by the University of Southampton has found that reusable catheters are just as safe for patients as single-use ones and do not increase the risk of urinary tract infections. The study followed hundreds of patients for a year and discovered that those who tested reusable catheters used 35 per cent fewer antibiotics.
A study published in Pediatric Research demonstrated the safety of intranasal breast milk therapy in brain-injured newborns. The therapy was found to be effective in supporting nervous system regeneration without causing any adverse effects.
A new review proposes a prevention-focused framework for understanding Parkinson's disease risk, highlighting the role of early-life vulnerability, environmental exposures, and resilience factors. The study suggests that susceptibility to PD may begin earlier in life through interactions between biology and environment.
A study using mice and simulations found that abdominal contractions compress blood vessels connected to the spinal cord and brain, enabling gentle brain movement that facilitates cerebrospinal fluid flow and potentially removes neural waste. This mechanism may explain why exercise is thought to benefit brain health.
A new study found that nearly 1,200 TBI respondents used psychedelics to treat or manage physical health conditions, with 208 participants using them to manage brain injury-related symptoms. Researchers reported a 90% self-reported symptom improvement rate.
Researchers developed a nasal spray that reversibly reduces brain inflammation, restores cellular power plants, and improves memory. The treatment bypasses the brain's protective shield through intranasal delivery, suppressing chronic inflammation and promoting successful brain aging.
Regulatory B cells produce anti-inflammatory cytokines like IL-10, which dampens inflammatory responses and guides T cells toward regulatory phenotypes. This immune modulation can counteract damaging inflammation and promote neuroprotection.
A retrospective study found that higher initial MP dose is associated with improved neurological outcomes in children with ANE. This suggests a potential benefit of more aggressive treatment for this rare but fatal condition.
A preliminary study suggests that red light therapy can protect against brain inflammation caused by repetitive head impacts in collegiate football players. The treatment, which involves shining near-infrared light at the brain through the skull, appeared to be effective in reducing inflammation throughout almost all regions of the brain.
Researchers at the University of Illinois discovered that propofol, a common anesthetic agent, can improve cognitive function after surgery in older individuals. Additionally, intranasal insulin was found to mitigate age-related memory impairment by modulating neuroinflammatory mechanisms.
The study found that S. birrea extract reversed behavioral alterations caused by monosodium glutamate, reduced oxidative stress parameters, and counteracted malondialdehyde levels. These results support the potential of S. birrea as a neuroprotective agent for preventing and treating cognitive deficits.
Researchers at the University of Virginia Health System are exploring the role of the neurovascular unit in maintaining healthy brain function and how damage can cause chronic health conditions. The studies aim to identify new biomarkers for blast-related brain injury and develop strategies for prevention and treatment.
A recent University of Michigan study sheds light on the critical protein Sarm1, which controls both nerve breakdown and regeneration. The research found that blocking Sarm1 boosts nerve regeneration but only if it preserves a delicate balance between protection and repair.
A systematic review and meta-analysis found that lithium supplementation did not significantly improve cognitive function in individuals with mild cognitive impairment or Alzheimer's disease. Alternative formulations like LIT-O may be a potential alternative to harness lithium's neuroprotective properties more efficiently.
Researchers developed a first-of-its-kind prenatal brain model to study cerebral hemorrhages on stem cells in preterm birth. An antidote reduced brain damage, and the study identified how neural stem cells are damaged by elevated interleukin-1 levels.
Researchers at UVA School of Medicine found that the breakdown of protective brain structures called perineuronal nets leads to social memory loss in Alzheimer's patients. Preventing the degradation of these nets may lead to new treatments to prevent or delay the disease.
Researchers at University of Tsukuba developed a technique to induce a deep hypothermic state, termed QIH, which significantly attenuated inflammation-associated glial cells and preserved neuronal integrity. This hibernation-like hypothermia may provide a safer and clinically viable therapeutic strategy for traumatic brain injuries.
Researchers discovered that triggering a reversible, hibernation-like hypothermic state in male mice improved motor performance and preserved neural health following brain injury. The study found less neuroinflammation and improved neuron survival in the injured brain area.
A new review from the University of Victoria suggests that psilocybin and 5-MeO-DMT may help treat concussions and traumatic brain injuries by increasing neuroplasticity and reducing inflammation. The compounds have shown promise in treating depression, anxiety, and other conditions in clinical research.
Researchers synthesized hybrid vitamin K analogues with enhanced neuroactive properties, exhibiting threefold greater potency in inducing neural progenitor cell differentiation compared to natural vitamin K. The compounds preserved vitamin K and retinoic acid's biological activity via the SXR and RAR receptors.
Researchers at UVA Health System are testing a cutting-edge MRI scanner to identify brain scarring caused by blast exposures in soldiers. If successful, the technology could lead to a new imaging test to diagnose brain changes caused by repeated blasts.
The JAK2-STAT3 pathway contributes to inflammation and injury after ischemic stroke. Targeting this pathway shows promise for reducing brain swelling, neuronal death, and improving recovery. Several inhibitors have been found effective in preclinical models, including Tyrphostin AG490, Ruxolitinib, and natural compounds like genistein.
A team of researchers has received a $3.2 million grant to upgrade the Generalized Blast Exposure Value (GBEV) tool, which assigns a numerical score to service members' blast exposure history to assess potential health outcomes.
A new technique using focused sound waves and microbubbles has shown great promise in treating debilitating brain lesions called cerebral cavernous malformations. The approach has halted the growth of lesions almost entirely, offering a potential paradigm shift in treatment.
Scientists have developed a sugar-coated nanotherapy that effectively traps misfolded proteins, neutralizing their toxic effects on neurons. The treatment significantly boosts the survival of lab-grown human neurons under stress from disease-causing proteins.
Researchers investigated the efficacy of a combination of atorvastatin and dexamethasone in treating patients with subacute subdural hematoma (sASDH). The study found significant symptom improvement and no recurrence or progression of symptoms in all five patients treated with this regimen. Non-surgical interventions for sASDH are ofte...
Researchers found that patients taking HIV drugs called NRTIs are substantially less likely to develop Alzheimer's disease. The study, led by Jayakrishna Ambati, analyzed data from two large health insurance databases and determined a significant reduction in Alzheimer's risk among patients on NRTIs.
Methyl eugenol has demonstrated notable antioxidant and antiproliferative activity, with potential therapeutic benefits for diseases like Alzheimer's disease and cancer. However, its toxicological risks, including hepatotoxicity and alterations in the gut microbiota, pose concerns for its application.
Researchers analyzed data from three trials and found nerinetide provided a clinically significant benefit to patients. The findings suggest that treating early, fast, and administering the drug can lead to improved patient outcomes.
A new drug-free intervention targets the root cause of progressive loss of neural function in SMA by gradually reawakening functionally silent motor neurons. Early results show improved leg muscle strength and walking in adults with SMA, regardless of symptom severity.
Researchers discovered that pancreatic β cells produce a neuroprotective agent called Fibroblast Growth Factor 23 (FGF23), which can stop amyloid-β-induced neuronal cell death. FGF23 may increase ribosomal proteins, helping to maintain homeostasis in neurons.
Researchers explore the role of efferocytosis in reducing inflammation and containing injury spread after an ischemic stroke. Efferocytosis may offer a promising therapeutic strategy to promote neural regeneration and minimize brain damage.
Researchers analyzed individual cells from two craniopharyngioma subtypes to identify specific cell types, their features, and interactions. The study found distinct cell types linked to tumor development and immune response in both adamantinomatous and papillary craniopharyngiomas.
New research highlights additional therapies being tested for hypoxic-ischemic encephalopathy (HIE) in newborns, including agents blocking glutamate receptor activation and antioxidant drugs. While therapeutic hypothermia is effective in high-income countries, its efficacy is uncertain in low- and middle-income nations.
A study published in The EMBO Journal reveals that PQBP3 plays a crucial role in stabilizing the nuclear membrane, which is destabilized in senescent cells and contributes to neurodegenerative disorders. PQBP3's dysfunction may lead to the degradation of Lamin B1, a protein essential for maintaining the nuclear membrane.
A study by Baylor College of Medicine researchers reveals that Tau protein mitigates neuronal damage caused by reactive oxygen species and promotes healthy aging. The findings support a new neuroprotective role for Tau against the toxicity associated with ROS.
Researchers discovered that amyloid fibrils can harness quantum superradiant effects to mitigate oxidative stress, potentially transforming dementia treatments and understanding of Alzheimer's disease. This finding raises questions about the conventional view of amyloid's role in the disease.
Researchers found that men taking terazosin-type medications had about a 40% lower risk of developing dementia with Lewy bodies compared to those taking tamsulosin or 5-alpha reductase inhibitors. The study suggests that these drugs may have broad potential for treating neurodegenerative conditions.
Research suggests that oxidative stress (OS) may trigger Alzheimer's disease and that enriching brain glutathione (GSH) could be a way forward. Clinical studies indicate GSH depletion in the hippocampus initiates early onset of AD prior to amyloid beta deposition and tau phosphorylation.
Scientists at Salk Institute explore the clinical potential of cannabinol (CBN) in treating traumatic brain injury, Alzheimer's disease, and Parkinson's disease. They identify four CBN analogs with improved neuroprotective ability and drug-like efficacy.
A novel drug principle has been successfully tested in a mouse model and brain organoids of ALS patients, preventing cell death and improving motor abilities. The discovery of the TwinF interface inhibitor FP802 offers a promising path for fighting ALS and could lead to the development of effective treatments.
ATH-1105, a small molecule positive modulator of the neurotrophic HGF system, demonstrates significant neuroprotective effects and extends survival in preclinical models of ALS. The study highlights the therapeutic potential of ATH-1105 in slowing or stopping neurodegeneration.
Researchers at UCLA Health have discovered that estriol, a pregnancy hormone, can repair damaged myelin in the brain's cortex of mice with multiple sclerosis. This finding offers hope for developing new treatments to address the disease's progression.
LSU Health New Orleans researchers found that a combination therapy using Neuroprotectin D1 and Resolvin D1 boosted brain cell survival, growth, and stability. The therapy showed promising results in reducing lesion volume and improving neurological function in acute ischemic stroke models.
Researchers found that progesterone can protect nerve cells from dying in people with Parkinson's disease. The study suggests that a balanced diet and steroid hormone-based therapeutic approaches could help slow down or stop the progression of neurodegenerative diseases.
A new neuroprotectant medication called ApTOLL has been shown to improve survival and reduce long-term disability among patients with stroke. The study found that ApTOLL, when used in conjunction with standard treatments, reduced death and brain damage, suggesting a promising new approach to treating stroke.
Researchers found that klotho has anti-inflammatory and neuroprotective effects on cultured glial cells, reversing increased secretion of pro-inflammatory cytokines. The study supports klotho's therapeutic potential in pathological processes with a neuroinflammatory component.
Researchers developed a lightweight, ultra-shock-absorbing foam that outperforms existing materials in mitigating concussions. The new material exhibits superior mechanical properties and can remain robustly shock-absorbing across various temperatures.
Researchers from UCLA have developed a strategy to identify novel treatments for cognitive decline and neurodegenerative diseases by exploiting sex differences in the brain. The study provides a roadmap for disentangling the contribution of sex-specific factors, which can yield treatments optimized for each sex.
Researchers at Okayama University discovered EPA's molecular target, which blocks purinergic chemical transmission and reduces pain perception. The study suggests EPA can be used as a therapeutic strategy for managing chronic pain with fewer side effects.
A new gene therapy approach using the neuroprotective protein SynCav1 has shown promising results in slowing down ALS disease progression and increasing life span in rodent models. The treatment preserved spinal cord motor neurons and extended longevity in mice, with similar effects observed in a rat model of ALS.
A novel subset of CD8+ regulatory-like T cells (CD8+TRLs) has been identified as 'first responders' to stroke, providing fast-acting and lasting protection. These cells reach the brain within 24 hours after stroke onset, releasing molecules that provide direct neuroprotective effects.
A team of experts encourages further investigation into the benefits of exercise training for managing multiple sclerosis. They argue that available studies are poorly designed and lack measurable neurological damage, suggesting that rigorous trials could provide evidence for neuroprotection.
Research reveals pridopidine enhances autophagy in ALS model, reducing toxic protein aggregation and promoting neuronal health. The study supports pridopidine's potential as a treatment for neurodegenerative diseases like Huntington's disease and Alzheimer's.
A randomized controlled trial found that consuming cranberries for 12 weeks improved participants' memory of everyday events and neural functioning. The study also showed a significant decrease in LDL or 'bad' cholesterol levels, contributing to improved vascular health and brain perfusion.
Researchers identified two genes associated with recovery within the first 24 hours after stroke, linking neuronal excitability to stroke outcomes. Genetic evidence suggests that calming overexcited neurons may protect the brain after a stroke.
Researchers have discovered that sigma 1 receptor plays a crucial role in protecting retinal ganglion cells from damage in glaucoma. The protein enables astrocytes to secrete supportive factors for neurons, improving their survival and function.